progression-free

progression-free

(prŏ-gresh′ŏn-frē″)
Pert. to a disease, such as cancer, that does not advance or become worse or more symptomatic.
References in periodicals archive ?
The combination of dabrafenib and trametinib achieves significant improvements in overall survival and progression-free survival in patients with untreated metastatic melanoma compared with treatment with vemurafenib alone, new data suggest.
SAN FRANCISCO -- Combination docetaxel and carboplatin therapy significantly improved progression-free survival among women with recurrent platinum-sensitive ovarian cancer, compared with sequential therapy in a randomized trial of 150 patients.
The new results were based on an analysis of archived tumor samples from 587 of the 1,198 patients in the CRYSTAL study, which had previously shown that some patients with metastatic disease benefited from cetuximab plus chemotherapy with respect to progression-free survival.
CHICAGO -- The addition of either of two doses of bevacizumab, a monoclonal antibody, to standard chemotherapy prolonged progression-free survival in patients with advanced non-small-cell lung cancer.
(NASDAQ: CELG) has presented results of the phase 3 AUGMENT study, which showed that Revlimid (lenalidomide) in combination with rituximab demonstrated superior progression-free survival in patients with relapsed/refractory indolent lymphoma compared to patients who received rituximab plus placebo (R-placebo), the company said.
Overall, 86% of patients remained progression-free at Week 72 of the study.
22, 2018 (HealthDay News) -- For patients with metastatic triple-negative breast cancer, atezolizumab plus nanoparticle albumin-bound (nab)-paclitaxel prolongs progression-free survival compared with placebo plus nab-paclitaxel, according to a study published online Oct.
M2 EQUITYBITES-July 27, 2018-Takeda announces improved progression-free survival in phase three ALTA-1L trial of Alunbrig
Nivolumab achieves significant improvements in overall survival and progression-free survival compared with conventional chemotherapy in untreated patients with advanced melanoma, regardless of PD-Ll status, according to data presented at the International Congress for the Society for Melanoma Research.
In a study sponsored by lapatinib manufacturer GlaxoSmithKline, progression-free survival was more than twofold higher among the women treated with the all-oral combination of these two agents, compared with those who received letrozole alone.
Trastuzumab combined with anastrozole in women with metastatic breast cancer whose disease was both estrogen receptor-positive and positive for the HER2 gene mutation was associated with double the progression-free survival and nearly 5 more months of overall survival than were achieved with anastrozole alone, according to new findings presented at the annual meeting of the European Society for Medical Oncology in Istanbul.